Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
News
First-line obinutuzumab monotherapy in CLL linked to good response, reduced toxicity
NEW YORK – Obinutuzumab monotherapy effective for the first-line treatment of chronic lymphocytic leukemia.
News
NF-kB inhibitor IT-901 shows promise in Richter syndrome
In vitro analyses of primary leukemic cells and in vivo analyses in patient-derived xenograft models indicate NF-kB inhibition should be...
News
Telomere length predicts FCR response in CLL patients
NEW YORK – Telomere length reliably predicts response to fludarabine-cyclophosphamide-rituximab (FCR) treatment in patients with chronic...
News
SOLE trial: Intermittent letrozole may provide benefit for some breast cancer patients
Temporary treatment breaks are acceptable in some breast cancer patients.
News
ALTTO follow-up: Dual HER2 blockade may benefit HER2+/HR- tumors
CHICAGO – HR– tumors may derive more benefit from dual HER2 blockade.
News
FDA advisory committee supports new CV liraglutide indication
A Food and Drug Administration advisory committee voted 17-2 in support of a supplemental new drug application for liraglutide (Victoza)...
News
Short-HER trial: DFS is similar, cardiac toxicity lower with short trastuzumab course
CHICAGO – Nine weeks of treatment with trastuzumab resulted in comparable disease-free and overall survival to that seen with the standard 12...
News
PORTEC-3: Possible benefit with combined CT/RT in high-risk endometrial cancer
Women with stage III endometrial cancer in the combined CT/RT arm experienced a statistically significant 11% improvement in FFS – defined as...
News
DESKTOP III: Secondary surgery for recurrent OC improves PFS, TFST
CHICAGO – Secondary cytoreductive surgery resulted in a clinically meaningful increase in progression-free survival and time to first subsequent...
News
ADT+RT duration can safely be shortened in high risk PC
CHICAGO – There may be a new standard of care on the horizon for patients with PC.
Video
VIDEO: Shorter oxaliplatin-based therapy suffices for some patients with stage III CRC
CHICAGO – There is a need for individualized therapy, which may result in shorter treatment durations and reduced toxicity.
Video
VIDEO: Pertuzumab prolongs disease-free survival in HER2+ early breast cancer
CHICAGO – The risk of an invasive disease-free survival event was reduced 19% when pertuzumab was added to adjuvant chemotherapy and trastuzumab...
Video
VIDEO: Survival improves when cancer patients self-report symptoms
CHICAGO – With improved survival and a host of other benefits, why wouldn’t you encourage your patients to self-report?
News
NOTCH1 mutation predicts reduced ofatumumab efficacy in CLL
NEW YORK – Consider CLL patients with NOTCH1 gene mutation for chemotherapy “without type1 CD20 antibodies or a treatment with novel compounds.”...
Video
VIDEO: Abiraterone improves survival in high-risk prostate cancer
CHICAGO – Adding abiraterone acetate plus prednisone to androgen deprivation therapy in hormone-naive prostate cancer patients significantly...